Holding the line: Ethics and surgical decision‐making in an era of financial pressure in health care systems around the globe

Abbreviations

ACL

anterior cruciate ligament

IRB

Institutional Review Board

Contemporary knee surgery operates at the intersection of scientific progress, clinical judgement, ethical responsibility and increasingly stringent economic constraints [4, 5]. Advances in imaging, biomechanics, biologics and implant technology have expanded the range of surgical options available to patients and healthcare providers. Concurrently, health care systems worldwide face growing financial pressure.

This convergence creates an unavoidable tension: how can surgeons ensure that care remains evidence‐based and ethically sound when reimbursement models and budgetary constraints increasingly shape clinical decision‐making?

Recent events underscore the urgency of this discussion. They raise a fundamental and troubling question for the orthopaedic community: where should the boundary be drawn between acceptable clinical interpretation and unjustifiable surgical indication in elective practice?

Surgical indication is rarely binary. Final recommendations are derived from a synthesis of symptoms, imaging findings, patient preferences, activity demands, psychosocial context and shared decision‐making. In elective procedures such as ACL reconstruction, meniscal surgery, cartilage repair or realignment osteotomies, surgeons must consider biological pathology, functional impairment, risk tolerance and nonoperative alternatives. However, when surgery is proposed in the absence of structural pathology or without a compelling pathophysiological rationale, the profession risks eroding public trust and undermining its ethical foundations.

At the same time, an equally concerning trend is emerging in several healthcare systems. In countries such as Germany, economic constraints and reimbursement frameworks increasingly discourage the adoption of novel, and often more costly, technologies—even when evidence suggests superior biological healing or lower complication rates. Surgeons may feel compelled to revert to older, less expensive and sometimes less effective methods. Meniscal surgery exemplifies this dilemma: despite accumulating evidence supporting tissue preservation and long‐term joint health, financial pressures may inadvertently favour partial meniscectomy or discourage modern repair strategies due to higher immediate cost.

These two phenomena, overtreatment at one extreme and inhibited innovation at the other, are not opposites. They are parallel manifestations of the same systemic pressures. When financial incentives, institutional metrics or regulatory frameworks start to shape clinical decision‐making, the central ethical principle of medicine is threatened: acting in the patient's best interest.

Where, then, should the line be drawn? It must be grounded in clearly defined, evidence‐based indications, continuous outcome monitoring and intellectual integrity [1, 3]. This approach requires acknowledging uncertainty, resisting commercial and institutional pressures and engaging patients in genuine shared decision‐making. It also entails meticulous documentation of pathology, transparent reporting of outcomes and rigorous evaluation of novel techniques through comparative trials and registry‐based surveillance.

In this context, scientific journals such as Knee Surgery, Sports Traumatology, Arthroscopy have a particular responsibility [2]. Beyond disseminating innovation, they must demand strict methodological rigour, balanced interpretation and clinically meaningful endpoints. Technical advances should be accompanied by high‐quality registries, randomised controlled trials, consensus statements and the publication of negative findings or no effects. Only through such transparency can surgeons be supported in making appropriate decisions, thereby protecting patients from both unnecessary procedures and obsolete care.

Collective engagement with policymakers, payers and hospital systems is also essential. Cost containment is an unavoidable component of modern health care, but it must not become a blunt instrument that stifles progress or incentivises inappropriate practice. Value‐based care should reward durable outcomes, joint preservation and patient‐reported success, rather than procedural volume or short‐term cost reduction alone.

High‐profile cases should not be regarded merely as isolated failures or controversies, but as catalysts for critical self‐reflection. Are our indications sufficiently precise? Are we adequately educating trainees about their ethical obligations? Do we generate robust evidence to justify both innovation and restraint? And do we possess the resilience to challenge systems that hinder our ability to act in the best interests of our patients?

One of the central challenges with contemporary knee surgery is achieving the right balance between economic reality and moral responsibility. Meeting this challenge demands humility, scientific rigour and ethical clarity. Above all, the patient must remain at the centre of every clinical decision.

Although the latest is not always the greatest, innovations have driven medicine and have improved the lives and life expectancy of people since the beginning of time. In 2026, we are on the brink of major orthopaedic innovation, breakthroughs, such as robotic intelligence, artificial intelligence, genetic phenotyping and antibody treatments of many major diseases, such as arthritis. All these innovations are expected to decrease patients disease, burden and improve quality of life. However, these innovations will carry with them high cost.

In order to control spending of healthcare dollars many joint ventures are being formed and private equity acquisitions of hospital systems have occurred. Organisations may then control both payer and provider, as well as pharmaceuticals. In this regard, the ethical code of the providing surgeon is often undermined, and surgical decision‐making is directed by the overall system, rather than the treating surgeon, regardless of ethical code. Therefore, we as orthopaedic surgeons have an obligation to advocate for improved treatment/decision‐making pathways with lawmakers and politicians.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

ETHICS STATEMENT

The authors have nothing to report.